Congress trades
Editas Medicine, Inc. (EDIT)
Free on iOS and Android.
About Editas Medicine, Inc.
from the company's filings and listing, as of Oct 20, 2026- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Gilmore O'Neill
- Employees
- 87
- Listed since
- Feb 3, 2016
- Market value
- $371.7M
- Price to earnings (12 mo)
- -
- Net income per share, as reported (12 mo)
- -$0.62
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 9, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 5, 2026 | -$0.15 | -$0.27 | $11.9M | $2.8M | EPS beat, GAAPRevenue beat |
| Q1 FY2026reported May 5, 2026 | -$0.26 | -$0.30 | $2.8M | $6.4M | EPS beat, GAAPRevenue miss |
| Q4 FY2025reported Mar 9, 2026 | -$0.06 | -$0.27 | $24.7M | $8.3M | EPS beatRevenue beat |
| Q3 FY2025reported Nov 10, 2025 | -$0.28 | -$0.38 | $7.5M | $8.5M | EPS beat, GAAPRevenue miss |
| Q2 FY2025reported Aug 12, 2025 | -$0.63 | -$0.41 | $3.6M | $1.8M | EPS miss, GAAPRevenue beat |
| Q1 FY2025reported May 12, 2025 | -$0.92 | -$0.56 | $4.7M | $642K | EPS miss, GAAPRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Apr 28, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Gilmore O’Neill, M.B., M.M.Sc.President and Chief Executive Officer | $687K | $0 | $1.7M | $2.4M |
| Linda C. Burkly, Ph.D.Executive Vice President and Chief Scientific Officer | $517K | $0 | $659K | $1.2M |
| Amy ParisonSenior Vice President and Chief Financial Officer | $394K | $0 | $427K | $822K |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. Executives who have since left are not shown. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| TCG Crossover Management, LLC | $36.0M | 11,111,111 | New | 9.31% |
| BlackRock, Inc. | $34.3M | 10,589,990 | +14.3% | 8.88% |
| RA Capital Management, L.P. | $28.8M | 8,889,000 | New | 7.45% |
| Commodore Capital LP | $28.8M | 8,889,000 | New | 7.45% |
| Adar1 Capital Management, LLC | $28.8M | 8,889,000 | New | 7.45% |
| Vanguard Capital Management LLC | $19.9M | 6,141,336 | +46.1% | 5.15% |
| Paradigm Biocapital Advisors LP | $18.1M | 5,586,625 | New | 4.68% |
| Opaleye Management Inc. | $12.5M | 3,861,930 | +100.4% | 3.24% |
| Vanguard Portfolio Management LLC | $11.7M | 3,598,339 | +14.3% | 3.02% |
| Woodline Partners LP | $11.5M | 3,555,497 | New | 2.98% |
| VIVO Capital, LLC | $11.5M | 3,555,250 | New | 2.98% |
| Gordonmd Global Investments LP | $10.1M | 3,127,000 | New | 2.62% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. New: not in this holder's prior 13F as reported; a change of filer ID can also show as new. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in EDIT
12 disclosures of 12 on record · median 24d of the 45 allowedSince the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 24, 2026), not the member's result. Not investment advice.
| Member | Type | Action | Amount disclosed | Stock since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Daniel S. Goldman | Stock | Sale | $1,001 - $15,000 | -63.8%After the saleS&P 500 +85.6% · -149.4 pts vs S&P 500 | Apr 10, 2023 | May 19, 2023 | 39d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | -94.2%After the saleS&P 500 +84.7% · -178.9 pts vs S&P 500 | Apr 14, 2021 | May 1, 2021 | 17d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | -94.7%After the saleS&P 500 +96.6% · -191.3 pts vs S&P 500 | Mar 2, 2021 | Apr 1, 2021 | 30d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -91.6%S&P 500 +110.8% · -202.5 pts vs S&P 500 | Nov 17, 2020 | Dec 1, 2020 | 14d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | -89.2%After the saleS&P 500 +168.9% · -258.1 pts vs S&P 500 | May 1, 2020 | May 31, 2020 | 30d |
| Donald S. Beyer, Jr.Joint | Stock | Sale | $1,001 - $15,000 | -90.5%After the saleS&P 500 +164.7% · -255.3 pts vs S&P 500 | Apr 27, 2020 | May 9, 2020 | 12d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -92.2%S&P 500 +132.8% · -224.9 pts vs S&P 500 | Jan 9, 2020 | Feb 22, 2020 | 44d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -91.4%S&P 500 +135.0% · -226.4 pts vs S&P 500 | Jan 27, 2020 | Feb 22, 2020 | 26d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -92.6%S&P 500 +136.7% · -229.2 pts vs S&P 500 | Dec 23, 2019 | Jan 2, 2020 | 10d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -90.4%S&P 500 +143.9% · -234.2 pts vs S&P 500 | Nov 19, 2019 | Dec 14, 2019 | 25d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -90.1%S&P 500 +144.6% · -234.7 pts vs S&P 500 | Nov 22, 2019 | Dec 14, 2019 | 22d |
| Donald S. Beyer, Jr.Joint | Stock | Purchase | $1,001 - $15,000 | -92.1%S&P 500 +142.3% · -234.4 pts vs S&P 500 | Dec 9, 2019 | Dec 14, 2019 | 5d |
Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no since-the-trade figure is computed from them.
Every Congress trade in EDIT, filterable by party, chamber, type and account.
Questions
Which members of Congress have traded EDIT?
Daniel S. Goldman and Donald S. Beyer, Jr. disclosed EDIT transactions in the filings shown here.
How quickly are EDIT trades disclosed?
Congressional disclosures took a median of 24 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.